Hepatitis C virus infection reduces hepatocellular polarity in a vascular endothelial growth factor-dependent manner

Gastroenterology. 2010 Mar;138(3):1134-42. doi: 10.1053/j.gastro.2009.11.047. Epub 2009 Nov 26.

Abstract

Background & aims: Hepatitis C virus (HCV) infection leads to progressive liver disease, frequently culminating in fibrosis and hepatocellular carcinoma. The mechanisms underlying liver injury in chronic hepatitis C are poorly understood. This study evaluated the role of vascular endothelial growth factor (VEGF) in hepatocyte polarity and HCV infection.

Methods: We used polarized hepatoma cell lines and the recently described infectious HCV Japanese fulminant hepatitis (JFH)-1 cell culture system to study the role of VEGF in regulating hepatoma permeability and HCV infection.

Results: VEGF negatively regulates hepatocellular tight junction integrity and cell polarity by a novel VEGF receptor 2-dependent pathway. VEGF reduced hepatoma tight junction integrity, induced a re-organization of occludin, and promoted HCV entry. Conversely, inhibition of hepatoma expressed VEGF with the receptor kinase inhibitor sorafenib or with neutralizing anti-VEGF antibodies promoted polarization and inhibited HCV entry, showing an autocrine pathway. HCV infection of primary hepatocytes or hepatoma cell lines promoted VEGF expression and reduced their polarity. Importantly, treatment of HCV-infected cells with VEGF inhibitors restored their ability to polarize, showing a VEGF-dependent pathway.

Conclusions: Hepatic polarity is critical to normal liver physiology. HCV infection promotes VEGF expression that depolarizes hepatoma cells, promoting viral transmission and lymphocyte migration into the parenchyma that may promote hepatocyte injury.

Publication types

  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Autocrine Communication
  • Benzenesulfonates / pharmacology
  • Carcinoma, Hepatocellular / metabolism
  • Carcinoma, Hepatocellular / pathology
  • Carcinoma, Hepatocellular / virology*
  • Cell Polarity*
  • Hep G2 Cells
  • Hepacivirus / pathogenicity*
  • Humans
  • Liver Neoplasms / metabolism
  • Liver Neoplasms / pathology
  • Liver Neoplasms / virology*
  • Membrane Proteins / metabolism
  • Niacinamide / analogs & derivatives
  • Occludin
  • Permeability
  • Phenylurea Compounds
  • Protein Kinase Inhibitors / pharmacology
  • Pyridines / pharmacology
  • Sorafenib
  • Tight Junctions / drug effects
  • Tight Junctions / metabolism
  • Tight Junctions / pathology
  • Tight Junctions / virology*
  • Up-Regulation
  • Vascular Endothelial Growth Factor A / metabolism*
  • Vascular Endothelial Growth Factor Receptor-2 / antagonists & inhibitors
  • Vascular Endothelial Growth Factor Receptor-2 / metabolism
  • Virus Internalization*

Substances

  • Benzenesulfonates
  • Membrane Proteins
  • OCLN protein, human
  • Occludin
  • Phenylurea Compounds
  • Protein Kinase Inhibitors
  • Pyridines
  • VEGFA protein, human
  • Vascular Endothelial Growth Factor A
  • Niacinamide
  • Sorafenib
  • Vascular Endothelial Growth Factor Receptor-2